CoVICIS EU-Africa Concerted Action on SAR-CoV-2 Virus Variant and Immunological Surveillance
- Coordinator
- Centre Hospitalier Universitaire Vaudois, Switzerland
- Runs
- 1 November 2021 to 30 April 2025
- Status
- Running
- EU funding
- €10.0m
- Total cost
- €10.0m
- Partners
- 16 organisations in 7 countries
- Type
- Research and Innovation Action
- Grant agreement
- 101046041
What the project is doing
In the project's own words, from its summary on CORDIS.
Despite of the successful advances achieved to date in the fight against the COVID-19 pandemic with the development of vaccines and therapy, the worldwide propagation of SARS-CoV-2 has resulted in the rapid evolution of this virus and in the emergence of variants of concern (VOC) that may dampen the efficacy of the first generation vaccines. To tackle the challenges associated with the VOC, the CoVICIS program is proposing a global approach with a powerful state-of-the-art virologic and immunologic platforms coupled with large genomic surveillance studies and diverse cohorts in EU and SSA.
This allows CoVICIS to contribute to the early identification of emerging VOC and address key unanswered questions regarding i) the susceptibility to infection with VOC after a prior infection in the setting of a long-COVID or after vaccination with different vaccines, ii) the risk posed by VOC in immunocompromised patients, and iii) the modalities of infection and immune responses in children. The diversity of the cohorts provides a unique opportunity to study virus evolution in different settings, where SARS-CoV-2-specific humoral and cellular immune responses are predicted to vary very significantly.
Beyond the genomic surveillance, the ground-breaking research and innovation of the program is the characterization of virologic and immunologic properties of VOC and the identification of immune correlates of protection after disease or vaccination. CoVICIS’ ambitious goals are only achievable thanks to the existing population studies and cohorts funded by national and international public agencies and public-private partnerships, and the combined collective expertise of CoVICIS partners in the fields of epidemiology, genomics, virology, immunology, data science and public health.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Centre Hospitalier Universitaire Vaudois | Lausanne | Switzerland | Coordinator |
| Ecole Polytechnique Federale De Lausanne | Lausanne | Switzerland | Participant |
| Eurovacc Foundation | Lausanne | Switzerland | Participant |
| Stiftung Swiss School of Public Health Plus (ssph) | Zurich | Switzerland | Participant |
| Universitat Zurich | Zurich | Switzerland | Participant |
| Universite De Geneve | Geneve | Switzerland | Participant |
| Klinikum Der Ludwig-Maximilians-Universitat Munchen | Munchen | Germany | Third party |
| Ludwig-Maximilians-Universitaet Muenchen | Planegg | Germany | Participant |
| Jimma University | Jimma | ET | Participant |
| Institut National De La Sante Et De La Recherche Medicale | Paris | France | Participant |
| Universita Degli Studi Di Milano | Milano | Italy | Participant |
| Stichting International Aids Vaccine Initiative the Netherlands | Amsterdam | Netherlands | Participant |
| South African Medical Research Council | Tygerberg | South Africa | Participant |
| Stellenbosch University | Stellenbosch | South Africa | Participant |
| University of Cape Town | Rondebosch | South Africa | Participant |
| Wits Health Consortium (pty) Ltd | Johannesburg | South Africa | Participant |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI